---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-025844"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2026-06-22T11:45:06+00:00"
generated_at: "2026-06-22T11:50:17.819242+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie to acquire Apogee Therapeutics for $135.11/share, ~$10.9B equity value

## Summary
- AbbVie to acquire all outstanding shares of Apogee for $135.11 per share in cash, total equity value ~$10.9 billion.
- Acquisition expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory clearances.
- Apogee's lead asset zumilokibart (APG777) targets IL-13 for atopic dermatitis; APG273 targets IL-13/TSLP for asthma.
- Voting agreement with certain stockholders to support merger; termination fee of $381.3M payable under specified conditions.

## SEC filing metadata
- accession: 0001140361-26-025844
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2026-06-22T11:45:06+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.07, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000114036126025844/0001140361-26-025844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000114036126025844/ef20076505_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-025844
- JSON: https://secwatch.observer/filing/0001140361-26-025844.json
- Plain text: https://secwatch.observer/filing/0001140361-26-025844.txt

## Key facts
- Material Agreements
  Apogee Therapeutics, Inc. entered into Agreement and Plan of Merger with Andor LLC, Andor Merger Co., and AbbVie Inc. valued at $135.11 per Share (effective 2026-06-18).
  - Action: entry
  - Agreement: merger
  - Counterparty: Andor LLC, Andor Merger Co., and AbbVie Inc.
  - Value: $135.11 per Share
  - Effective: 2026-06-18
  source text: On June 18, 2026, Apogee Therapeutics, Inc. (the “Company” or “Apogee”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Andor LLC, a Delaware limited liability company and a wholly owned subsidiary of Guarantor (“Parent”), Andor Merger Co., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and solely for the limited purposes set forth therein, AbbVie Inc., a Delaware corporation (“Guarantor” or “AbbVie”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1974640/000114036126025844/0001140361-26-025844-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.